A cryo formulation-based microneedle device for transdermal delivery of bioactive therapeutic agents. The microneedle device includes: one or more microneedle patches each including an array of miniaturized needles, wherein each miniaturized needle defining a base end and a tip; and a substrate to which the base end of the array of miniaturized needles is attached or integrated thereto; wherein the microneedle patch is in a cryo status; wherein each of the one or more microneedle patch is adapted to be applied on a skin surface, in which the miniaturized needles penetrates into skin; wherein the miniaturized needles is further arranged to melt so as to release one or more bioactive therapeutic agents into the skin to achieve a targeted therapeutic effect; and wherein the bioactive therapeutic agents includes protein and/or antigens.

Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.

A multi chamber syringe unit includes a longitudinal body with side wall, distal end side, proximal end side opposite to distal end side, an interior limited by side wall between distal end side and proximal end side and distal opening arranged in distal end side for providing a liquid out of the body. The syringe further includes a separating element arranged in the interior of the body such that distal chamber and proximal chamber are formed in the interior of the body, wherein the separating element seals the distal chamber from the proximal chamber. The syringe has a bypass arrangement provided in the side wall of distal chamber of the body. A first pharmaceutical liquid is arranged in distal chamber of the body and second pharmaceutical liquid in proximal chamber of the body. The multi chamber syringe unit allows for adequately administering plural pharmaceutical liquids by injection.

Methods and systems for utilizing co-simulation of a physical model and a self-adaptive predictive controller using hybrid automata are described. For example, there is disclosed a self-adaptive predictive control system to generate an initial patient model with initial patient model settings (k.sub.1, k.sub.2, . . . , k.sub.n) and execute a program that takes as input, the initial patient model settings as configuration parameters that specify at least a plurality of initial states. Such a system further receives new patient inputs and generates hybrid automata as a variation of the initial states by applying the new patient inputs to the initial patient model. The system further derives reachable states from the hybrid automata and outputs all reachable states computed. The system further detects changes and responsively generates a new patient predictive model with new parameter settings (k′.sub.1, k′.sub.2, . . . , k′.sub.n), iteratively repeating until a termination criterion is satisfied. Other related embodiments are disclosed.

The present invention relates to a cryopreserved in vitro cell culture comprising human pancreatic progenitor cells that co-express pancreatic-duodenal homeobox factor-1 (PDX1) and NK6 homeobox 1 (NKX6.1) and are chromogranin negative. The present invention also relates to a method for cryopreserving an in vitro population of human pancreatic progenitor cells that co-express PDX1 and NKX6.1 and are chromogranin negative.

An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.

Embodiments include methods and systems for maintaining glucose homeostasis. Systems can include a pump, a first reservoir including a homeostasis agent, an umbilical catheter capable of being advanced in the umbilical vein or in the falciform ligament, and a sensor. Systems can also include a biocompatible coating, a microprocessor in communication with the pump and the sensor, and a power supply. Methods can include implanting a pump and reservoir subcutaneously in a patient, advancing a catheter in the umbilical vein or in the falciform ligament, measuring a blood glucose level, pumping a homeostasis agent, and administering the homeostasis agent to the portal venous system.

The invention relates generally to methods of treating or reducing the risk of Cytokine Release Syndrome (CRS), treating or reducing the risk of Tumor Lysis Syndrome (TLS), or increasing drug exposure in a subject undergoing CAR T-cell therapy or chemotherapy. The methods comprise contacting blood from the subject with an extracorporeal membrane having a plurality of pores having an average pore size of at least 60 kDa to permit inflammatory cytokines, other inflammatory molecules, or metabolites to pass through the pores and out of the blood that is returned back to the subject.

The invention relates to a dialysis device that provides recirculating flow dialysis in a wearable and portable format. It uses an exchangeable purification unit holding a volume of dialysate and/or a sorbent system for the in-situ regeneration of dialysate. The invented dialysis device comprises a carrier that is mounted on a replaceable cartridge. The carrier holds the electronics, user-interface, actuators and sensors. It actuates, controls and monitors the dialysis operation. The cartridge is a replaceable part that is connected to the patient via a flexible tubing. It consists of a reusable housing with a memory chip and holds a disposable inlay containing the purification unit with fluid lines, connectors, dialysate and/or sorbents in combination with a nanofilter. The cartridge is intended for use during the day, as a wearable system. The cartridge can be enlarged with an extension set to offer more capacity. The extended cartridge is intended to be used during the night as a bedside device.

An embodiment provides a method for treating a body fluid, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an antigen in the body fluid to form an antibody-antigen complex; removing the antibody-antigen complex from the body fluid; and returning the body fluid to the patient. Other aspects are described and claimed.